403 reports of this reaction
2.2% of all UMECLIDINIUM reports
#7 most reported adverse reaction
CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #7 most commonly reported adverse reaction for UMECLIDINIUM, manufactured by GlaxoSmithKline LLC. There are 403 FDA adverse event reports linking UMECLIDINIUM to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 2.2% of all 18,218 adverse event reports for this drug.
Patients taking UMECLIDINIUM who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for UMECLIDINIUM, but still significant enough to appear in the safety profile.
In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for UMECLIDINIUM:
The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 403 FDA reports for UMECLIDINIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 2.2% of all adverse event reports for UMECLIDINIUM, making it a notable side effect.
If you experience chronic obstructive pulmonary disease while taking UMECLIDINIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.